A new type of digital therapy that helps cancer patients fight off the infection could help prevent terminal cancer patients from passing the disease to others.
Digital therapeutics, also known as digital medicine, is the latest form of treatment for cancer, and it has the potential to be a game-changer in the fight against cancer.
It’s a technology that has revolutionised the way doctors treat cancer patients, by making it possible to deliver medication that targets the cancer cells without harming the healthy cells.
The digital therapy developed by the National Institute for Health Research (NIHR) has the ability to block cancer cells from multiplying and then attacking healthy cells, said the director of the university’s Centre for Advanced Digital Technology (CART) Dr Helen Smith.
“The effect is that the cancer has to be removed, not replanted,” she said.
“So the cancer doesn’t cause the infection, which is the killer of most cancer.”
Now you can put the patient in a bed for a month with no side effects.
“It’s like having a drug for a cancer.”
Digital therapy can be delivered by either intravenous (IV) or intranasal (IN), or injected.
The technology is based on a molecule called an adenosine monophosphate (AMP), which is found in the body.
The adenosines, when injected, cause cells to release certain proteins, including a protein called cyclin D1, which can kill cancer cells.
“This is a very simple molecule,” Dr Smith said.
“It has no known toxic effects.
It also has no effect on normal cells.”
Dr Smith said that the adenosin monophosate molecule, which has been found in cancer cells, can be used to deliver digital therapy to patients in a way that is safe and effective.
“Our technology is designed to be injected or injected, and then the patient can take it intravenously or intramuscularly,” she explained.
“We can deliver it in a small volume, so that it’s safe and it’s not a toxic drug.”
The new digital medicine treatment, called the COVID-19 vaccine, is designed as a non-toxic vaccine that targets cancer cells and does not cause any side effects, Dr Smith explained.
The team is also developing a new type, called COVID, that targets cancers in the liver, which may be more resistant to the adeno-associated virus, which causes cancer.
The research, conducted by CART and the University of Adelaide, has been published in the Journal of the American Medical Association (JAMA).
The researchers say that while the results are promising, it is not yet clear if this type of therapy is safe, effective or effective.
The study was supported by the UK Government’s National Cancer Research Centre, the Australian Cancer Council, the European Union, the Irish Cancer Foundation, the World Cancer Research Fund, the National Health Service, the International Agency for Research on Cancer (IARC), the United Nations Scientific Committee on the Effects of Chemicals on Health (UNSCEH) and the National Institutes of Health.
For more on cancer and the news you care about, subscribe to our new weekly newsletter, The Irish Time, here.